Cycloserine

Cycloserine

SCHEMBL5146943

NC(=O)O.NC1CONC1=O.O=C(O)CO

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

alrddl

The experimentally established mechanism targets of Cycloserine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BLM P54132 2/20 0.66
MEN1 O00255 1/20 0.66
GRIN2D O15399 1/20 0.66
LMNA P02545 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2C9 P11712 1/20 0.66
TSHR P16473 1/20 0.66
PTGS1 P23219 1/20 0.66
MAPK1 P28482 1/20 0.66
KMT2A Q03164 1/20 0.66
GRIN1 Q05586 1/20 0.66
GRIN2A Q12879 1/20 0.66
GRIN2B Q13224 1/20 0.66
GRIN2C Q14957 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
HIF1A Q16665 1/20 0.66
HSD17B10 Q99714 1/20 0.66
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL21801698 0.86 BLM (0.70) BLMMEN1GRIN2DLMNACYP3A4
Succinic Acid SCHEMBL21801699 0.86 BLM (0.70) BLMMEN1GRIN2DLMNACYP3A4
Cycloserine SCHEMBL18584681 0.81 BLM (1.00) BLMMEN1GRIN2DLMNACYP3A4
Cycloserine SCHEMBL8681114 0.81 BLM (1.00) BLMMEN1GRIN2DLMNACYP3A4
Cycloserine SCHEMBL34323 0.81
Cycloserine SCHEMBL6571320 0.79
Cycloserine SCHEMBL10448776 0.79
Maleic Acid SCHEMBL21801700 0.79 TSHR (0.70) BLMMEN1GRIN2DLMNACYP3A4
Maleic Acid SCHEMBL21801701 0.79 TSHR (0.70) BLMMEN1GRIN2DLMNACYP3A4
Cycloserine SCHEMBL21359249 0.77 BLM (0.68) BLMMEN1GRIN2DLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453837-A4 TARGETED THERAPEUTICS AND USES THEREOF ACTIVBIOTICS INC (US) 2007-11-07 EP disclosed
US-7122525-B2 Targeted therapeutics and uses thereof ACTIVBIOTICS, INC. (US) 2006-10-17 US disclosed
EP-1453837-A2 TARGETED THERAPEUTICS AND USES THEREOF Activbiotics, Inc. (US) 2004-09-08 EP disclosed
US-20040063718-A1 Targeted therapeutics and uses thereof ACTIVBIOTICS PHARMA LLC 2004-04-01 US disclosed
WO-2003045319-A2 TARGETED THERAPEUTICS AND USES THEREOF ACTIVBIOTICS, INC. (US) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063718-A1 Targeted therapeutics and uses thereof CD47, RIF1, NUP205 BLM 1324/4885MEN1 1939/4885GRIN2D 4833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.